MicroPort Scientific Corporation provided consolidated earnings guidance for the full year ended December 31, 2021. For the year, the Group achieved double digit year-on-year growth in sales revenue, which was principally attributable to rapid market penetration in the endovascular and peripheral vascular devices business, the cardiac
rhythm management business, the neurovascular business and the heart valve business, contribution from new product launches, and the increase in elective surgeries from the easing of the COVID-19 pandemic. During the Reporting Period, the Group recorded loss attributable to equity shareholders of the Company of between approximately USD 275 million and USD 285 million, as compared with a loss of USD 191 million for the same period of last year.